Spero Therapeutics inks Jefferies at-the-market equity distribution deal for up to $100 million
SPRO•Jefferies agreement for at-the-market sales
Spero Therapeutics entered an Open Market Sale Agreement with Jefferies for an at-the-market common stock offering.
Planned sales are sized up to $100 million under a universal shelf registration statement that is not yet effective.
Jefferies will act as sales agent using commercially reasonable efforts, with a fee of up to 3% of gross proceeds.
Prior Cantor Fitzgerald agreement terminated
The company terminated its prior Cantor Fitzgerald controlled equity offering agreement.
No shares were sold under that program in 2024 or 2025.
